Pliant snags $287.5 million in oversubscribed public offering amid market uncertainty
Pliant Therapeutics' recent fundraise to boost its rare disease pipeline comes when experts predict a challenging public market.

Pliant Therapeutics' recent fundraise to boost its rare disease pipeline comes when experts predict a challenging public market.
The Xiannuoxin and VV116 oral small-molecule drugs are developed to treat mild to moderate Covid-19 adult patients.
Merck recorded a 1% rise in pharmaceutical sales to $12.18bn compared to $12.03bn in the prior-year quarter.
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
Health Canada accepts Veru’s Covid-19 therapy NDS-CV for review
South Korea authorises Novavax Covid-19 vaccine as booster dose
BioNTech to buy UK-based AI company InstaDeep
India’s Hetero receives WHO approval for Nirmacom to treat Covid-19